Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pulse BiosciencesPLSE +8.17%31 3-Year EBITDA Growth Rate is 11.80% as of Mar. 2026, which is 178% above its 10-year median of 4.25. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Pulse Biosciences ranks better than 54.12% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pulse Biosciences was 25.60% per year. The lowest was -62.90% per year. And the median was 4.25% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pulse Biosciences 3-Year EBITDA Growth Rate Related Terms
PLSE vs LMAT, ATRC, XRAY: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.80% mean?
Pulse Biosciences (PLSE) has a 3-Year EBITDA Growth Rate of 11.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pulse Biosciences and its competitors. This is 178% above median its historical median of 4.25. According to the industry distribution chart, Pulse Biosciences ranks #317 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 45.9%.
Is Pulse Biosciences' 3-Year EBITDA Growth Rate too high?
Pulse Biosciences' current 3-Year EBITDA Growth Rate of 11.80% is 178% above median its 10-year median of 4.25. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Pulse Biosciences' value of 11.80% is 45.7% above this industry median. Based on the distribution chart, Pulse Biosciences ranks #317 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' 3-Year EBITDA Growth Rate compare to LMAT and ATRC?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #317 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Pulse Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Pulse Biosciences' value of 11.80% is 45.7% above this benchmark. While the company's 10-year median is 4.25 vs. the industry median of 8.10, Pulse Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pulse Biosciences's current 3-Year EBITDA Growth Rate of 11.80% is 45.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current 3-Year EBITDA Growth Rate is 11.80%, which is 178% above median its own 10-year median of 4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current 3-Year EBITDA Growth Rate of 11.80%. The current 3-Year EBITDA Growth Rate is 11.80%, which is 178% above median its 10-year median of 4.25 and 45.7% above the Medical Devices & Instruments industry median of 8.10. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current 3-Year EBITDA Growth Rate is 11.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
